扶正散瘀法对中晚期食管癌放疗增效的研究分析(4)
[10]O′Donovan TR，Rajendran S，O′Reilly S，et al.Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo[J].PLOS ONE，2015，10(8)：e0134676.
[11]Rios-Doria J，Sabol D，Chesebrough J，et al.A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways[J].Mol Cancer Ther，2015，14(7)：1637-1649.
[12]馬纯政，王蓉，张明智，等.化痰散瘀法联合化疗治疗中晚期食管癌30例临床观察[J].中医杂志，2013，54(15)：1301-1303，1307.
[13]Jivan R，Damelin LH，Birkhead M，et al.Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines[J].J Cell Biochem，2015，116(10)：2334-2343.
[14]Honjo S，Ajani JA，Scott AW，et al.Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer[J].Int J Oncol，2014，45(2)：567-574.
[15]Chen J，Lan T，Zhang W，et al.Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma(ESCC)cells via suppression of PI3K/AKT and Stat3 pathways[J].Arch Biochem Biophys，2015，1(575)：38-45.
[16]李超，孙仁煌，王凤琴.颈及胸上段食管癌调强放疗的临床研究[J].中国医药导刊，2017，19(1)：17-18.
[17]Yang P，Tuo L，Wu Q，et al.Licochalcone-A sensitizes human esophageal carcinoma cells to TRAIL-mediated apoptosis by proteasomal degradation of XIAP[J].Hepatogastroenterology，2014，61(133)：1229-1234.
[18]Wang J，Yang ZR，Guo XF，et al.Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer[J].Mol Med Rep，2014，10(5)：2535-2541.
[19]吴敏.三维适形放疗联合化疗及消癌平治疗局部晚期食管癌的临床疗效观察[J].中国实用医药，2014，4(15)：146-146，147.
[20]武二伟，齐洪志，赵化荣，等.167例中晚期食管癌放化疗的疗效及预后[J].现代肿瘤医学，2017，25(3)：385-389.
[21]Kwon J，Yoon HJ，Kim JH，et al.Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma[J].Oncol Rep，2014，32(3)：1188-1192.
[22]张德智，王璐瑶，梁怀虹.中晚期食管癌患者3D-CRT同步化疗的临床效果[J].中国实用医药，2017，12(3)：25-27., http://www.100md.com(赵艳莉 吴召利 千维娜)
[11]Rios-Doria J，Sabol D，Chesebrough J，et al.A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways[J].Mol Cancer Ther，2015，14(7)：1637-1649.
[12]馬纯政，王蓉，张明智，等.化痰散瘀法联合化疗治疗中晚期食管癌30例临床观察[J].中医杂志，2013，54(15)：1301-1303，1307.
[13]Jivan R，Damelin LH，Birkhead M，et al.Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines[J].J Cell Biochem，2015，116(10)：2334-2343.
[14]Honjo S，Ajani JA，Scott AW，et al.Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer[J].Int J Oncol，2014，45(2)：567-574.
[15]Chen J，Lan T，Zhang W，et al.Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma(ESCC)cells via suppression of PI3K/AKT and Stat3 pathways[J].Arch Biochem Biophys，2015，1(575)：38-45.
[16]李超，孙仁煌，王凤琴.颈及胸上段食管癌调强放疗的临床研究[J].中国医药导刊，2017，19(1)：17-18.
[17]Yang P，Tuo L，Wu Q，et al.Licochalcone-A sensitizes human esophageal carcinoma cells to TRAIL-mediated apoptosis by proteasomal degradation of XIAP[J].Hepatogastroenterology，2014，61(133)：1229-1234.
[18]Wang J，Yang ZR，Guo XF，et al.Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer[J].Mol Med Rep，2014，10(5)：2535-2541.
[19]吴敏.三维适形放疗联合化疗及消癌平治疗局部晚期食管癌的临床疗效观察[J].中国实用医药，2014，4(15)：146-146，147.
[20]武二伟，齐洪志，赵化荣，等.167例中晚期食管癌放化疗的疗效及预后[J].现代肿瘤医学，2017，25(3)：385-389.
[21]Kwon J，Yoon HJ，Kim JH，et al.Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma[J].Oncol Rep，2014，32(3)：1188-1192.
[22]张德智，王璐瑶，梁怀虹.中晚期食管癌患者3D-CRT同步化疗的临床效果[J].中国实用医药，2017，12(3)：25-27., http://www.100md.com(赵艳莉 吴召利 千维娜)